Golgi-enzyme guided cancer nanomedicines to overcome resistance
Official title: Golgi enzyme-instructed self-assembly for molecular anticancer nanomedicines
Funded at Brandeis University · NIH-11390100 · Data updated 2026-11-12
A new approach uses enzymes at the Golgi to assemble tiny cancer-fighting nanostructures inside tumor cells, aiming to stop growth and spread.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project start | February 8, 2010 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $447,762 |
| NIH project number | 2R01CA142746-16 |
| Project ID | NIH-11390100 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients whose cancer shows resistance to standard therapies and whose tumors could be studied for Golgi-targeted nanomedicine approaches.
✕Less likely to help
Patients with cancers that do not respond to or tolerate this mechanism may not benefit.
What this research studies
This grant explores a unique way to turn cancer proteins into self-assembling nanomedicines right where cancer cells live. By triggering assembly at the Golgi, doctors hope to weaken cancer cells and reduce resistance to treatment. The work builds on prior findings that these nanostructures can stop tumor growth and metastasis in models, with a focus on making them selective for cancer cells. Researchers will test how well this approach works in cells and animal models to move toward possible therapies.
Why it matters
Potential benefit: If successful, patients could receive more targeted treatments that overcome resistance and limit tumor growth.
How similar studies have gone: Previous work with self-assembling anti-cancer nanomedicines showed tumor growth inhibition, supporting the potential of this approach.
Where this research is happening
-
Brandeis University
Waltham, United States Active
Researchers
- Principal investigator: Xu, Bing — Brandeis University
- Study coordinator: Xu, Bing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.